Please login to the form below

Not currently logged in
Email:
Password:

Reasanz

This page shows the latest Reasanz news and features for those working in and with pharma, biotech and healthcare.

Novartis will file heart failure drug before year-end

Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a ... Novartis is currently conducting a second phase III

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics